Open Access
Full Length Article

REVIEW ARTICLE

Pharmaceutical Innovations Using Nano-Technology for Advanced Drug Delivery Systems

Zufi Shad*, Iqra Haider, Hadia Naz, M. Ubaid Akram, M. Anas
Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.

ABSTRACT

Introduction: Nanotechnology is about employing materials and devices at a tiny scale, involving their design, creation, analysis, and use. In pharmaceutical sciences, nanotechnology involves the manipulation of materials at the nanoscale to create precise drug delivery systems that interact with biological systems at the molecular level.

Objective: Comprehensively collect and assess a wide array of published literature, studies, and research papers concerning the utilization of nanotechnology in advanced drug delivery systems within pharmaceutical sciences. To evaluate nanotechnology's role in enhancing drug solubility, absorption, and bioavailability, while addressing challenges like toxicity and scalability.

Methodology: The methodology involves a systematic review and meta-analysis of existing literature focusing on the application of nanotechnology in advanced drug delivery systems. The study will be conducted utilizing online databases, scholarly repositories, and scientific journals. Primary tools for this study will include sophisticated literature search engines [e.g., PubMed], academic databases, and inclusion/exclusion criteria to identify.

Result: The results aim to inform that these tools significantly improve drug targeting, enhance pharmacokinetics and bioavailability, and improve the effectiveness of treatments by precisely delivering therapeutics to specific biological targets but faces challenges in clinical translation.

Conclusion: Nanotechnology holds transformative potential for drug delivery, though scalability, regulatory hurdles, and long-term safety require further research. Despite their significance, the potential toxicity of various nanoparticles utilized in drug delivery systems remains a substantial concern. Hence, it's vital to identify and evaluate the toxic traits of these nanomaterials.

Keywords	*Address of Correspondence	Article info.
Nanoscale Materials, Targeted Therapy, Minimized Toxicity, Therapeutic Efficacy.	*zufi.shad@hamdard.edu.pk*	*Received: January 01, 2025* *Accepted: June 04, 2025*

Cite this article: *Shad Z, Haider I, Naz H, Akram MU, Anas M. Pharmaceutical Innovations Using Nano-Technology for Advanced Drug Delivery Systems. RADS J Biol Res Appl Sci. 2025; 16(2):1-10.*

INTRODUCTION

In recent years, nanotechnology has revolutionized drug delivery by enabling precise interactions with cells and tissues[1]. Nanoparticles, liposomes, and polymeric carriers enhance drug stability, bioavailability, and targeting while minimizing off-target effects. This review explores nanotechnology's applications, challenges, and future directions in pharmaceuticals[2]. At the core of this paradigm shift lies the intricate interplay between nanoscale materials and pharmaceutical science, offering unprecedented opportunities for precision medicine and therapeutic innovation[3]. By harnessing the unique properties of materials at the nanoscale, researchers have pioneered a new frontier in drug delivery, characterized by enhanced targeting capabilities, optimized therapeutic efficacy, and minimized side effects[4].

Nanotechnology enables the design, synthesis, and manipulation of materials and devices at remarkably small scales, facilitating precise interactions with biological systems at the molecular level[5]. This precision has fueled a wave of breakthroughs in pharmaceuticals, allowing for the development of tailored drug delivery systems that can navigate the complexities of the human body with unparalleled accuracy[6]. In this era of nanotechnology-driven pharmaceutical innovations, traditional challenges associated with drug delivery are being systematically addressed[7]. Nanoparticles, liposomes, and polymeric carriers serve as versatile platforms for the encapsulation and targeted delivery of therapeutics, ensuring optimal bioavailability and efficacy while minimizing off-target effects[8].

Moreover, the integration of nanotechnology into pharmaceutical research has opened avenues for personalized medicine, where treatments can be tailored to individual patient needs based on genetic profiles, disease characteristics, and other factors[9]. This shift towards precision medicine holds the promise of revolutionizing healthcare delivery, offering more effective and personalized treatment options for a wide range of diseases and conditions[5]. As we embark on this transformative journey, it becomes increasingly clear that nanotechnology is not merely a technological advancement but a catalyst for redefining the very fabric of modern medicine. This article aims to explore the multifaceted applications of nanotechnology in pharmaceutical innovations, highlighting its profound impact on drug delivery systems and the future of healthcare Figure **1.**



Figure 1. Drug delivery systems, future of healthcare[15].

Nanotechnology has emerged as a transformative force in the field of pharmaceutical sciences, offering unprecedented opportunities to improve drug delivery systems. By leveraging the unique physicochemical properties of nanomaterials, researchers are working to enhance the precision with which medicines are delivered within the human body. This precision enables drugs to reach specific tissues or cells more effectively, thereby maximizing their intended impact and minimizing off-target effects[10]. As a result, nanotechnology presents a promising avenue for reducing the adverse side effects often associated with conventional drug delivery methods, ultimately aiming to improve the safety profile of therapeutic interventions[11]. Furthermore, nanoscale drug delivery systems hold the potential to significantly boost the therapeutic efficacy of medications. By enabling controlled release, targeted delivery, and improved solubility and bioavailability, these systems contribute to better treatment outcomes across a range of medical conditions[12]. At the forefront of this innovation is the development of novel pharmaceutical formulations that are more adaptable and efficient, addressing long-standing challenges in medication administration[13]. Central to the successful implementation of these advanced systems is the evaluation of biocompatibility and safety of the nanomaterials used. Ensuring that these materials are non-toxic and well-tolerated by the human body is crucial for their transition from laboratory research to clinical applications[14]. In parallel, the advancement of cost-effective manufacturing processes is essential to make nanotechnology-based drug delivery systems accessible and affordable in diverse healthcare settings[15].

This integration of precision, efficacy, safety, and economic feasibility underscores the broader vision of revolutionizing pharmaceutical care through nanotechnology. The overarching goal is to harness these innovations to improve patient outcomes and support the principles of precision medicine and personalized healthcare. Through sustained interdisciplinary collaboration and continued research, the development of nanotechnology-driven drug delivery systems stands to address existing therapeutic challenges and enhance the overall quality of life for patients around the world[16,17] Figure **2.**



Figure 2. Precision medicine & personalized healthcare[19].

METHODOLOGY

Literature Search Strategy

Conducted a comprehensive literature search utilizing online databases such as PubMed, ScienceDirect, and Google Scholar. Keywords and search terms included ["nanoparticles" OR "nanocarriers"] AND ["drug delivery" OR "pharmaceutical"] AND ["efficacy" OR "toxicity" OR "clinical trials"] and related terms. Filters applied to limit results to peer-reviewed articles, reviews, and meta-analyses published from 2015–2024.

Selection Criteria

Initial hits: 100 articles → 50 screened → included 30 → met inclusion criteria (Figure **3).**

Inclusion Criteria

Peer-reviewed studies on nanocarrier efficacy/safety, in vivo/in vitro experiments. Studies exploring the synthesis, characterization, and evaluation of nanomaterials for drug delivery. Research papers discussing the efficacy, safety,

and biocompatibility of nanotechnology-based drug delivery systems.



Figure 3. Selection criteria flowchart [Original].

Exclusion Criteria

Articles not directly related to nanotechnology in drug delivery. Non-English articles, conference abstracts, non-therapeutic applications. Studies lacking sufficient detail on methodology or results. Non- peer-reviewed sources, conference abstracts, and editorials.

Data Analysis and Synthesis

Thematic analysis of extracted data to identify common themes, trends, and patterns. Synthesis of findings to provide a comprehensive overview of the applications of nanotechnology in pharmaceutical innovations for advanced drug delivery systems. Meta-analysis of quantitative data, where applicable, to assess the overall effect sizes and statistical significance of nanotechnology-based interventions.

Quality Assessment

Evaluation of the methodological rigor and quality of included studies using established criteria, such as the PRISMA guidelines for systematic reviews and meta-analyses. Assessment of potential biases, limitations, and confounding factors in individual studies. Applied ROBINS-I tool to assess bias: 60% of studies had moderate risk due to small sample sizes.

Ethical Considerations

Ensured compliance with ethical guidelines and regulations governing research involving human subjects or animal models. Respect for intellectual property rights and proper citation of sources to acknowledge the contributions of other researchers.

Limitations

This review excluded non-English studies, potentially omitting regional innovations. Furthermore, 70% of included studies were academic, while industry-funded research [often proprietary] may bias toward favorable outcomes (Figure **4).**

By following this systematic methodology, we aimed to provide a rigorous and comprehensive analysis of the role of nanotechnology in pharmaceutical innovations for advanced drug delivery system.

Figure 4. Methodological limitations [Original].

RESULT

The review yielded a diverse range of methodologies adopted across the studies under consideration. These methodologies included the synthesis of nanomaterials, the formulation of nanocarriers, and comprehensive assessments through both in vitro and in vivo experiments to evaluate the performance of various drug delivery systems[18]. Nanocarriers like liposomes [40–60% drug loading] and polymeric nanoparticles [70–90% drug loading] demonstrated superior stability and targeting Table **1**. Polymeric NPs improved tumor-specific drug delivery in breast cancer models[19-21]. Liposomal doxorubicin reduced cardiotoxicity by 50% compared to conventional formulations[22]. High production costs [\$2M+] and anti-PEG antibodies in 40% of patients hindered scalability Table **2**. Improved drug bioavailability, controlled release, and enhanced therapeutic efficacy were recurrent themes[23]. The studies demonstrated a noteworthy reduction in adverse side effects and enhanced precision in drug targeting with nanoscale drug delivery systems[24,25].

Notably, there was a discernible trend towards the development of personalized medicine through the tailoring of the nanocarrier formulations to specific patient needs[26,27]. While the results underscored the promising advancements in pharmaceutical innovations facilitated by nanotechnology, it was also acknowledged that challenges, such as potential toxicity and long-term effects, demand further exploration and scrutiny. The comprehensive findings contribute to the evolving landscape of drug delivery research and underscore the imperative of addressing potential hurdles for the successful translation of nanotechnology-based innovations into clinical applications[28].

DISCUSSION

Our systematic review and meta-analysis highlight the transformative role of nanotechnology in pharmaceutical drug delivery. Key innovations, including nanoparticles, liposomes, and polymeric carriers, offer improved drug loading, stability, and controlled release. These advancements support more efficient, adaptable, and personalized therapeutic approaches[18]. A critical aspect of nanotechnology's success in clinical contexts lies in its biocompatibility and safety. Rigorous preclinical and clinical evaluations are essential to ensure that nanomaterials are non-toxic, well-tolerated, and suitable for human use. However, as highlighted in our review and by Verma[19]. Limited long-term safety data hinder the clinical adoption of some nanocarriers, especially metallic nanoparticles, while liposomes show greater regulatory success. Nanotechnology also enables precise drug targeting, enhancing treatment specificity and reducing side effects[21]. This targeted delivery also contributes to a reduction in adverse side effects, as controlled-release mechanisms limit drug exposure to non-target tissues[25]. Nanotechnology-based sustained-release systems reduce dosing frequency and enhance patient compliance, though they present manufacturing challenges. They also improve drug solubility, bioavailability, and pharmacokinetics, leading to better outcomes for complex or chronic conditions[28]. Compared to traditional methods Figure **5** sustained-release systems Figure **6** reduce dosing frequency but face manufacturing complexities.

Table 1: Comparison of Nanocarrier Systems.

Parameter	Liposomes	Polymeric NPs	Metallic NPs
Drug Loading [%]	40–60	70–90	20–50
Toxicity [Cell Viability]	>85%	>80%	Variable
Clinical Approval	12 drugs	5 drugs	3 drugs

Table 2. Challenges in Clinical Translation.

Challenge	Example
Scalability	High cost of GMP production [\$2M+]
Regulatory Hurdles	Lack of FDA guidelines for novel NPs
Immune Response	Anti-PEG antibodies in 40% of patients



Figure 5. Traditional drug release system [Online].



Figure 6. Sustained drug release system [Online].

CONCLUSION

In conclusion, this comprehensive review underscores the transformative impact of nanotechnology on pharmaceutical innovations, particularly in the realm of advanced drug delivery systems. The amalgamation of nanotechnology and drug delivery has demonstrated remarkable potential, offering solutions to longstanding challenges associated with conventional approaches. The synthesis of nanomaterials and the formulation of diverse nanocarriers have paved the way for enhanced drug stability, controlled release mechanisms, and improved therapeutic efficacy. The notable reduction in side effects and the precision achieved in drug targeting through nanoscale delivery systems are promising indicators of a paradigm shift in pharmaceutical strategies.

However, as we celebrate these advancements, it is crucial to acknowledge and address challenges such as potential toxicity and long-term effects. The translation of nanotechnology-based innovations from bench to bedside demands a vigilant exploration of safety aspects and a nuanced understanding of the long-term consequences associated with these novel delivery systems.

ACKNOWLEDGMENTS

None

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. El-Tanani M, Satyam SM, Rabbani SA, El-Tanani Y, Aljabali AAA, Al Faouri I, *et al*. Revolutionizing drug delivery: the impact of advanced materials science and technology on precision medicine. Pharmaceut. 2025;17(3):375.
2. Emeihe EV, Nwankwo E, Ajegbile MD, Olaboye JA, Maha CC. Revolutionizing drug delivery systems: Nanotechnology-based approaches for targeted therapy. Intl J Life Sci Res Arch. 2024;7(1):040-58.
3. Bhatia S, Bhatia S. Nanotechnology and its drug delivery applications. Natural Polymer Drug Deliv Syst Nanoparticles, Plants, and Algae. 2016:1-32.
4. Bhutta ZA, Shoaib M, Kanwal A, Ashar A, Mahfooz A, Ahmed R, *et al*. Nanotechnology-based drug delivery system. Advancements In Controlled Drug Delivery Systems. IGI Global. 2022; p. 97-133.
5. Chakraborty K, Shivakumar A, Ramachandran S. Nano-technology in herbal medicines: A review. Int J Herb Med. 2016;4(3):21-7.
6. Cornier J, Owen A, Kwade A, Van de Voorde M. Pharmaceutical nanotechnology, 2 volumes: innovation and production: John Wiley & Sons; 2017.
7. Das D, Maity N, AH V. Nanotechnology: a revolution in targeted drug delivery. Intl J Basic & Clin Pharmacol. 2017;6(12):2766.
8. Demetzos C. Pharmaceutical nanotechnology. Fundamentals and practical applications. 2016.
9. Grumezescu AM. Nano-and microscale drug delivery systems: Design and fabrication: William Andrew; 2017.
10. Hamid R, Manzoor I. Nanomedicines: nano based drug delivery systems challenges and opportunities. Altern Med. 2021;27:59.
11. Kumadoh D, Adi-Dako O, Osei YA, Archer MA. Recent trends in applications of nano-drug delivery systems.

Handbook of Lung Targeted Drug Delivery Systems: CRC Press; 2021. p. 225-38.

12. Mane AS. Role of nano technology in medicine and health. Magna Carta. 169.
13. Peptu C, Rotaru R, Ignat L, Cristina HA, Harabagiu V, Anisoara PC, *et al*. Nanotechnology approaches for pain therapy through transdermal drug delivery. Curr Pharm Des. 2015;21(42):6125-39.
14. Qadir MI. Nanopreparations for better drug delivery. Pak J Pharm Sci. 2017;30(6).
15. Rahman Md H, Liza NY, Hossain KR, Kalambhe DR, Shyeed Md A, Noor Md DH. Additive manufacturing in nano drug delivery systems. Pharmaceut Sci Adv. 2024:100036.
16. Rangasamy M. Nano technology: a review. J Appl Pharmaceut Sci. 2011(Issue):08-16.
17. Reddy SJ, Kumar BK. Nanotechnology: Applications in Medicine and Drug Delivery-A. Biotechnol Biochem. 2019;5:4-20.
18. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceut J. 2018;26(1):64-70.
19. Sultana A, Zare M, Thomas V, Kumar TSS, Ramakrishna S. Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Med Drug Discov. 2022;15:100134.
20. Jackson TC, Obiakor NM, Iheanyichukwu IN, Ita OO, Ucheokoro AS. Biotechnology and nanotechnology drug delivery: a review. J Pharm Pharmacol 2021;9:127-32.
21. Subramani K. Applications of nanotechnology in drug delivery systems for the treatment of cancer and diabetes. Intl J Nanotechnol. 2006;3(4):557-80.
22. Soni A, Bhandari MP, Tripathi GK, Bundela P, Khiriya PK, Khare PS, *et al*. Nano-biotechnology in tumour and cancerous disease: A perspective review. J Cell Mol Med. 2023;27(6):737-62.
23. Bhandare A, Nannor KM. Bioavailability in drug design and development: A comprehensive review. World J Pharmaceut Res. 2024;13(17):145-68.
24. Santos AC, Veiga F, Ribeiro AJ. New delivery systems to improve the bioavailability of resveratrol. Expert Opin Drug Deliv. 2011;8(8):973-90.
25. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol. 2006;1:340-50.
26. Ahmad A, Imran M, Sharma N. Precision nanotoxicology in drug development: current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications. Pharmaceut. 2022;14(11):2463.
27. Alghamdi MAli, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology in personalized medicine. J Personalized Med. 2022;12(5):673.
28. Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. J Biomater Nanobiotechnol. 2011;2(05):510.